Pancreatic Ductal Adenocarcinoma.

Monogr Clin Cytol

Department of Pathology, Jupiter Medical Center, Jupiter, Florida, USA.

Published: October 2021

The most frequent indication for pancreatic fine-needle aspiration sampling is to confirm or exclude a pancreatic ductal adenocarcinoma (PDAC). PDAC is the most common malignant neoplasm of the pancreas, and the term pancreatic cancer typically connotes this entity. The conventional type of PDAC is a tubular adenocarcinoma, with a number of morphological variations described. Morphologically distinct but related entities include adenosquamous carcinoma, undifferentiated carcinoma, and undifferentiated carcinoma with osteoclast-type giant cells. Unrelated carcinomas with ductal lineage include colloid carcinoma and medullary carcinoma. Less commonly reported carcinomas include signet ring cell carcinoma, hepatoid carcinoma, and oncocytic carcinoma. Here we will focus on the cytological findings of PDAC and other carcinomas of ductal lineage, briefly touching upon their clinical features, histologic appearance, and clinically useful serum markers. The differential diagnosis, pitfalls, and useful ancillary studies will also be reviewed. A diagnosis of PDAC should not be taken lightly given that it can potentially result in a pancreatic resection. Familiarity with the entities described in this review will help practicing cytopathologists confront these cases with appropriate information needed in order to render a clinically valuable diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000455736DOI Listing

Publication Analysis

Top Keywords

pancreatic ductal
8
ductal adenocarcinoma
8
carcinoma
8
carcinoma undifferentiated
8
undifferentiated carcinoma
8
carcinomas ductal
8
ductal lineage
8
pancreatic
5
pdac
5
adenocarcinoma frequent
4

Similar Publications

Elevated protein lactylation promotes immunosuppressive microenvironment and therapeutic resistance in pancreatic ductal adenocarcinoma.

J Clin Invest

January 2025

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Metabolic reprogramming shapes tumor microenvironment (TME) and may lead to immunotherapy resistance in pancreatic ductal adenocarcinoma (PDAC). Elucidating the impact of pancreatic cancer cell metabolism in the TME is essential to therapeutic interventions. "Immune cold" PDAC is characterized by elevated lactate levels resulting from tumor cell metabolism, abundance of pro-tumor macrophages, and reduced cytotoxic T cell in the TME.

View Article and Find Full Text PDF

Background: Damage-associated molecular patterns (DAMPs) induced by immunogenic cell death (ICD) may be useful for the immunotherapy to patients undergoing pancreatic ductal adenocarcinoma (PDAC). The aim of this study is to predict the prognosis and immunotherapy responsiveness of PDAC patients using DAMPs-related genes.

Methods: K-means analysis was used to identify the DAMPs-related subtypes of 175 PDAC cases.

View Article and Find Full Text PDF

Updates in the Surgical Management of Pancreatic Ductal Adenocarcinoma.

Gastroenterol Clin North Am

March 2025

Department of Surgery, University of Minnesota, 420 Delaware Street SE, MMC 195, Minneapolis, MN 55455, USA. Electronic address:

Surgical management of pancreas cancer is complex, including the timing of surgery, surgical approach, intraoperative techniques, and postoperative management, which are reviewed in detail in this manuscript. Ultimately, referral to a high-volume pancreatic surgeon or pancreatic surgery center is critical to ensuring appropriate short-term and long-term outcomes.

View Article and Find Full Text PDF

Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis.

Cell Rep Med

January 2025

State Key Laboratory of Systems Medicine for Cancer, Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:

Pancreatic ductal adenocarcinoma (PDAC) relies heavily on glutamine (Gln) utilization to meet its metabolic and biosynthetic needs. How epigenetic regulators contribute to the metabolic flexibility and PDAC's response and adaptation to Gln scarcity in the tumor milieu remains largely unknown. Here, we elucidate that prolonged Gln restriction or treatment with the Gln antagonist, 6-diazo-5-oxo-L-norleucine (DON), leads to growth inhibition and ferroptosis program activation in PDAC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!